GC Therapeutics
GC Therapeutics (GCTx) is a pioneering biotechnology company that has developed the world's first "plug-and-play" induced pluripotent stem cell (iPSC) programming platform called TFome™. This platform integrates synthetic biology, gene editing, cell engineering, and machine learning to overcome the complexities of cell therapy development and scaling. GCTx aims to deliver off-the-shelf iPSC-based medicines up to 100 times faster than conventional methods with improved potency, efficiency, quality, and cost. Their pipeline focuses on potential best-in-class cell therapies targeting gastrointestinal, neurological, and immunological diseases. Founded by leading scientists including George Church, Ph.D., the company is positioned to significantly improve patient access to advanced cell therapies and reduce healthcare burdens.
GC Therapeutics
GC Therapeutics (GCTx) is a pioneering biotechnology company that has developed the world's first "plug-and-play" induced pluripotent stem cell (iPSC) programming platform called TFome™. This platform integrates synthetic biology, gene editing, cell engineering, and machine learning to overcome the complexities of cell therapy development and scaling. GCTx aims to deliver off-the-shelf iPSC-based medicines up to 100 times faster than conventional methods with improved potency, efficiency, quality, and cost. Their pipeline focuses on potential best-in-class cell therapies targeting gastrointestinal, neurological, and immunological diseases. Founded by leading scientists including George Church, Ph.D., the company is positioned to significantly improve patient access to advanced cell therapies and reduce healthcare burdens.